ORLANDO, Jan. 22 -- An investigational therapeutic vaccine for pancreatic cancer extended survival after surgery by about six to seven months, researchers reported here.
The median overall median survival for patients who received the vaccine was 26.8 months versus historical survival of about 20 months, said Daniel A. Laheru, M.D., of Johns Hopkins.
Eighty-eight percent of the patients who received the vaccine survived for a year, and the two-year survival rate was 76%, Dr. Laheru said at a gastrointestinal cancer symposium. Published trials of patients treated with surgery alone reported an average one-year survival of 63% and a two-year survival rate of 42%.
The vaccine, which is administered by infusion, consists of lethally irradiated lines of pancreatic cancer cells that are engineered to secrete granulocyte macrophage colony stimulating factor (GM-CSF).